Year: 2017

Drugs Inducing Necroptotic Cell Death As A New Strategy for High Grade Serous Ovarian Cancer

We recently demonstrated that chemotherapy resistant ovarian cancer stem-like cells (CSC) can be identified by a protein activity known as ALDH…

Read on

Systematic Discovery of LncRNA Interactome in Epithelial Ovarian Cancer

Ovarian cancers (OCs) are highly aggressive malignancies and cause more deaths than any other cancers of the female reproductive system. Survival rates for OCs are very poor: for advanced disease only ~30% of patients survive beyond 5 years…

Read on

Development of Targeted Therapies for Recurrent Ovarian Cancer

The mortality rates in many major forms of cancer have been reduced over the past decade. However, the mortality rate for ovarian cancer has not been significantly improved…

Read on

EZH2 Determines PARPi Resistance and Fork Stabilization in Ovarian Tumors

Epithelial ovarian cancers (EOCs) are late-diagnosed and lethal tumors. A high percentage of EOCs initially respond to current therapies but eventually develop resistance. This greatly reduces patient survival…

Read on

Rational Immunity to Improve Survival Following Standard-of-care Chemo

Ovarian cancer is the leading cause of death among gynecologic malignancies, and dramatic improvements in overall survival remaining wanting…

Read on

BRCA-Independent DNA Repair Pathways in Ovarian Cancer

DNA within human cells is continuously subject to various damaging agents. These agents often cause DNA double-strand breaks (DSBs), which can be repaired by a process known as homology-directed repair (HDR)…

Read on

Epigenetic Causes of Acquired Resistance to Anti-VEGF Therapy

Anti-angiogenic therapy with bevacizumab along with chemotherapy is a useful and approved regimen in the U.S.; however, most tumors rapidly adapt and develop resistance to such drugs…

Read on

Precision Medicine in Ovarian Cancer: Using Single Cell Analysis

Despite progress in the understanding of tumor biology, clinical trials designed using specialized new therapies against specific biologic and genetic changes in patient’s tumors commonly fail…

Read on